Market Overview

Biogen No Longer 'Too Risky,' Atlantic Analyst Sees Massive Upside

  • Biogen Inc (NASDAQ: BIIB) shares have been on a downtrend since March 20, and are down 13 percent year-to-date.
  • Atlantic Equities’ Steve Chesney initiated coverage of the company with an Overweight rating and a price target of $344.
  • With multiple pipeline opportunities moving to late-stage and higher risk opportunities reporting proof of concept data, Biogen’s risk/reward appears attractive, Chesney stated.

Growth for Biogen’s lead multiple sclerosis [MS] asset Tecfidera appears to be stabilizing as of 3Q15, analyst Steve Chesney said. He expects mid-single digit growth through the end of this decade.

Chesney added that challenges to the remaining MS portfolio, including Avonex and Tysabri, are “well understood,” and projected about 2 percent growth for the base business through 2020.

In the report Atlantic Equities noted, “We believe investor perceptions of the BIIB pipeline as “too early-stage/too high-risk” are poised to change as some of the lower risk pipeline moves onto the market and mid-stage drugs move into late-stage clinical trials in 2016.”

There are potential approvals for the partnered MS portfolio, including Zinbryta and ocrelizumab. Chesney expects Phase III to begin for MT-1303 in ulcerative colitis, raxatrigine in pain, and aducanumab in Alzheimer’s Disease in 2016. “Our base-case assumes 50% chance of approval for this Phase III pipeline and our base case DCF indicates $344/ share.”

Provided the Phase III pipeline succeeds, there is potential for de-risked 2020 revenue CAGR of about 10 percent.

“Given the lack of proof of concept data for the other Alzheimer’s pipeline, such as E2609 (BACE inhibitor) and BAN2401 (anti-Aβ) and anti-LINGO for MS, we await the Phase II data before including these in our scenario analysis,” Chesney wrote. He added, however, that each of them potentially represent “multi-billion dollar opportunities.”

Latest Ratings for BIIB

Nov 2020RBC CapitalMaintainsSector Perform
Nov 2020DZ BankUpgradesHoldBuy
Nov 2020B of A SecuritiesDowngradesNeutralUnderperform

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings


Related Articles (BIIB)

View Comments and Join the Discussion!

Posted-In: Atlantic Equities Steve ChesneyAnalyst Color Long Ideas Initiation Analyst Ratings Trading Ideas

Latest Ratings

HYMCBMO CapitalInitiates Coverage On
DEMorgan StanleyMaintains335.0
SBNYRaymond JamesMaintains138.0
CORTHC Wainwright & Co.Maintains32.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at